LIMITED TARIFF BENEFIT DISCLOSURE STATEMENT

Provide a signed hard copy to the Clerk of the Senate Committee on Finance located at 219 Dirksen SOB and a PDF version sent via email to mtb2009@finance-dem.senate.gov not later than five business days after the date of introduction of the bill. *Please be aware that this form will be made available to the public, media, and any other interested parties.*

Part I. This form is being submitted for S. 2507, which I introduced in the Senate on October 29, 2009. If the bill referenced above is a modification of a previously introduced bill to reflect technical changes, please indicate the previous bill number here: S. _____.

Part II. Please indicate the type of disclosure below: (Please check one only)
☒ The bill referenced in Part I is reasonably anticipated to benefit 10 or fewer individuals or entities, and as such constitutes a Limited Tariff Benefit. (Complete Part III)
☐ The bill referenced in Part I is reasonably anticipated to benefit more than 10 individuals or entities, and as such does not constitute a Limited Tariff Benefit.

Part III. Provide the information below in subparts A, B, and C if the bill referenced above is a Limited Tariff Benefit.

A. Anticipated Beneficiaries:

EMS-CHEMIE (North America) Inc.

B. Purpose of the Limited Tariff Benefit:
This bill would suspend the general rate of duty on:

N,N,N′,N′-Tetrakis(2-hydroxypropyl)adipamide (CAS No. 57843–53–5) provided for in subheading 3824.90.4090)

C. Financial Benefit Certification
☒ I hereby certify that neither I nor my immediate family has a financial interest in the above described limited tariff benefit.

(Member Signature) Date 11-3-09

Lindsey O. Graham
(Print Member name)